Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma

NCT03909412 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT03909412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03909412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma
Lead sponsor
Hackensack Meridian Health
Phase
Phase 1
Overall status
Recruiting
Start date
October 8, 2019
Completion date
August 31, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma